Tenshi Kaizen (TK) is focussed on delivering advanced finished dosage products driven by proprietary technology platforms, global infrastructure, and a robust quality system. Our strategy is aligned with the founder’s ethos of producing reliable and cost-effective pharmaceuticals with speed and agility.  Building on our strong global network, we are committed to fulfilling the demands of the world markets by anticipating the future needs and pioneering strategic new in-roads into the commercial pharmaceutical sector.

Different types of cancer have unique molecular ‘fingerprints’ which are detectable in early stages of the disease and can be picked up with near-perfect accuracy by small, portable scanners in just a few hours, according to a study published today in the journal Molecular Cell.

The antiviral drug tecovirimat did not reduce the time to lesion resolution or have an effect on pain among adults with mild to moderate clade II mpox and a low risk of developing severe disease, according to an interim data analysis from the international clinical trial called the Study of Tecovirimat for Mpox (STOMP). There were no safety concerns associated with tecovirimat.

Suven Pharmaceuticals Limited a technology-leading CDMO specializing in complex and innovative drug modalities, has announced the acquisition of a controlling stake in NJ Bio Inc. with an investment of  USD 64.4 million.

CSIR covers a wide spectrum of science and technology – from oceanography, geophysics, chemicals, drugs, genomics, biotechnology and nanotechnology to mining, aeronautics, instrumentation, environmental engineering and information technology. It provides significant technological intervention in many areas concerning societal efforts, which include environment, health, drinking water, food, housing, energy, farm and non-farm sectors. Further, CSIR’s role in S&T human resource development is noteworthy.